Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Report: Oxford chief says there’s ‘small chance’ COVID-19 vaccine is ready by Christmas

By Sean Whooley | November 4, 2020

The director of the group developing a COVID-19 vaccine candidate at Oxford University says it’s possible that the vaccine could be ready by Christmas.

According to a Reuters report, Oxford vaccine trial chief investigator Andrew Pollard said he’s optimistic that the university, which is collaborating with AstraZeneca on the vaccine, will present trial results by the end of 2020.

The trial hit a slight snag in September when AstraZeneca voluntarily paused the U.S. trial after a standard review process was triggered so an independent committee could review safety data surrounding an unexplained illness that occurred in the UK Phase III trial for the AZD1222 vaccine candidate. Last month, the FDA expanded its probe into the British drugmaker.

Speaking to British lawmakers, Pollard said the vaccine is “getting closer” to the point at which it can be reviewed by regulators. He was then asked if he expected that the vaccine could begin to be deployed before Christmas, which is something the British National Health Service (NHS) is preparing for, according to the report.

“There is a small chance of that being possible but I just don’t know,” Pollard said.

The Oxford and AstraZeneca vaccine candidate is considered a frontrunner among the several candidates out there, including Pfizer and BioNTech’s candidate, which could be submitted for FDA emergency use authorization (EUA) at the end of this month.

Tell Us What You Think! Cancel reply

Related Articles Read More >

AstraZeneca-Oxford
Study finds AstraZeneca COVID-19 vaccine could be effective against Brazil variant
RCSB Protein Data Bank now has more than 1,000 SARS-CoV-2 proteins
Data sciencea
Q&A: Keys to unlock data science potential for drug discovery
Ivermectin not supported for mild COVID-19, study says

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards